Tech Company Financing Transactions
Heartseed Funding Round
Heartseed closed a $14.2 million Series D venture capital round on 5/25/2023. Backers included Arcus South East Asia, private investors and Japan Co-Invest Limited Partnership.
Transaction Overview
Company Name
Announced On
5/25/2023
Transaction Type
Venture Equity
Amount
$14,219,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to complete the Phase 1/2 clinical trial of its lead asset, HS-001 for HF in Japan, as well as to establish an organization for its launch, and examine a less invasive administration such as transendocardial injection using a catheter for global development by Novo Nordisk.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
302-9 Art Complex Center 12-9 Daikyocho, Shinjuku-ku
Tokyo, 160-0015
JP
Tokyo, 160-0015
JP
Phone
Undisclosed
Website
Email Address
Overview
Developer of a myocardial regenerative medicine intended to transform the treatment of severe heart failure. The company's medicines specialize in cardiac cells from iPS cells which are transplanted directly into the heart of patients with ischemic heart disease such as myocardial infarction and dilated cardiomyopathy, enabling patients with heart disease to avoid artificial dialysis treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keiichi Fukuda
Browse more venture capital transactions:
Prev: 5/25/2023: Tools for Humanity venture capital transaction
Next: 5/25/2023: Signaloid venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs